JP4740525B2 - 脈管疾患の予防および治療のためのコーティングされた医療装置 - Google Patents
脈管疾患の予防および治療のためのコーティングされた医療装置 Download PDFInfo
- Publication number
- JP4740525B2 JP4740525B2 JP2003140878A JP2003140878A JP4740525B2 JP 4740525 B2 JP4740525 B2 JP 4740525B2 JP 2003140878 A JP2003140878 A JP 2003140878A JP 2003140878 A JP2003140878 A JP 2003140878A JP 4740525 B2 JP4740525 B2 JP 4740525B2
- Authority
- JP
- Japan
- Prior art keywords
- stent
- rapamycin
- drug
- drug delivery
- delivery device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
- A61F2002/91541—Adjacent bands are arranged out of phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/0097—Coating or prosthesis-covering structure made of pharmaceutical products, e.g. antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Description
本特許出願は、2002年5月20日出願の米国仮特許出願第60/381,986号の恩典を請求するものであって、2000年5月12日出願の米国仮特許出願第60/204,417号の恩典を請求する2000年5月19日出願の米国特許出願第09/575,480号の一部継続出願である2001年5月7日出願の米国特許出願第09/850,293号の一部継続出願である。
クローズ,A.W.(Clowes, A.W.)およびカモフスキー,M.(Kamovsky, M.)著,「ネイチャー(Nature)」,第265巻,1977年,25頁乃至26頁 ガイトン,J.R.(Guyton, J.R.)他著,「シー・アイ・アール・シー・リサーチ(Circ. Res.)」,第46巻,1980年,625頁乃至634頁 クローズ,A.W.(Clowes, A.W.)およびクローズ,M.M.(Clowes, M.M.)著,「ラボラトリー・インベスティゲーション(Lab. Invest.)」,第52巻,1985年,611頁乃至616頁 クローズ,A.W.(Clowes, A.W.)およびクローズ,M.M.(Clowes, M.M.)著,「シー・アイ・アール・シー・リサーチ(Circ. Res.)」,第58巻,1986年,839頁乃至845頁 マジェスキー(Majesky)他著,「シー・アイ・アール・シー・リサーチ(Circ. Res.)」,第61巻,1987年,296頁乃至300頁 スノー(Snow)他著,「アメリカン・ジャーナル・パソロジー(Am. J. Pathol.)」,第137巻,1990年,313頁乃至330頁 オカダ,T.(Okada, T.)他著,「ニューロサージャリ−(Neurosurgery)」,第25巻,1989年,92頁乃至98頁 コルヒチン(クーリエ,J.W.(Currier, J.W.)他著,「シー・アイ・アール・シー(Circ.)」,第80巻,1989年,11頁乃至66頁 ソロット,S.J.(Sollot, S.J.)他著,「ジャーナル・クリニカル・インベスティゲーション(J. Clin. Invest.)」,第95巻,1995年,1869頁乃至1876頁 パウエル,J.S.(Powell, J.S.)他著,「サイエンス(Science)」,1989年,第245巻,186頁乃至188頁 ランデルガン,C.F.(Lundergan, C.F.)他著,「アメリカン・ジャーナル・カージオロジー(Am. J. Cardiol.)」,1991年,第17巻(別冊B),132B頁乃至136B頁 ジョナッソン,L.(Jonasson, L.)他著,「ピー・アール・オー・シー・エヌ・エー・ティー・エル・アカデミック・ソサイエティー(Proc. Natl. Acad. Sci.)」,1988年,第85巻,2303頁 ファーンズ,G.A.A.(Ferns, G.A.A.)他著,「サイエンス(Sience)」,1991年,第253巻,1129頁乃至1132頁 ネメセック,G.M.(Nemecek, G.M.)他著,「ジャーナル・ファマコロジー・イー・エクス・ピー・テラピー(J. Pharmacol. Exp. Thera.)」,1989年,248巻,1167頁乃至1174頁 リウ,M.W.(Liu, M.W.)他著,「シー・アイ・アール・シー(Circ.)」,1990年,81巻,1089頁乃至1093頁 フクヤマ,J.(Fukuyama, J.)他著,「ヨーロピアン・ジャーナル・ファーマコロジー(Eur. J. Pharmacol.)」,1996年,第318巻,327頁乃至332頁 ハンソン,G.K.(Hansson, G.K.)およびホルム,J.(Holm, J.)著,「シー・アイ・アール・シー(Circ.)」,1991年,第84巻,1266頁乃至1272頁 マークス,S.O.(Marx, S.O.)他著,「シー・アイ・アール・シー・リサーチ(Circ. Res.)」,1995年,76巻,412頁乃至417頁 コルバム,M.D.(Colbum, M.D.),他,ジャーナル・バスキュラー・サージェリー(J. Vasc. Surg.),15巻,510頁乃至518頁,1992年 バーク,B.C.(Berk, B.C.)他著,「ジャーナル・アメリカン・シー・オー・エル・エル・カージオロジー(J. Am. Coll. Cardiol.)」,1991年,第17巻,111B頁乃至117B頁 ワインバーガー,J.(Weinberger, J.)他著,「インターナショナル・ジャーナル・ラジエーション・オー・エヌ・シー・バイオロジー・フィジクス(Int. J. Rad. Onc. Biol. Phys.)」,1996年,第36巻,767頁乃至775頁 ファーブ,A.(Farb, A.)他著,「シー・アイ・アール・シー・リサーチ(Circ. Res.)」,1997年,第80巻,542頁乃至550頁 シモンズ,M.(Simons, M.)他著,「ネイチャー(Nature)」,1992年,第359巻,67頁乃至70頁 チャン,M.W.(Chang, M.W.)他著,「ジャーナル・クリニカル・インベステイゲーション(J. Clin. Invest.)」,1995年,第96巻,2260頁乃至2268頁
(A)治療的な投与量の一或いは複数の化合物の腔内医療装置からのプロフィール放出により制御された送達を含む標的病変再狭窄の予防方法。
(1)前記一或いは複数の化合物の腔内医療装置からのプロフィール放出が、前記治療的な投与量の第1の濃度の前記一或いは複数の化合物でステントの第1の部分をコーティングするステップと、前記治療的な投与量の第2の濃度の前記一或いは複数の化合物で前記ステントの第2の部分をコーティングするステップとを含み、前記第2の濃度が前記第1の濃度よりも高いことを特徴とする実施態様(A)に記載の標的病変再狭窄の予防方法。
(2)前記一或いは複数の化合物がラパマイシンを含むことを特徴とする実施態様(1)に記載の標的病変再狭窄の予防方法。
(3)前記一或いは複数の化合物がラパマイシンを含むことを特徴とする実施態様(A)に記載の標的病変再狭窄の予防方法。
(4)前記一或いは複数の化合物が、高親和性の細胞質タンパク質であるFKBP12に結合する類似体、誘導体、および同族体を含み、ラパマイシンと同じ薬理学的特性を有することを特徴とする実施態様(A)に記載の標的病変再狭窄の予防方法。
(5)前記一或いは複数の化合物の腔内医療装置からのプロフィール放出が、前記治療的な投与量の第1の濃度の前記一或いは複数の化合物でステントの第1の部分をコーティングするステップと、前記治療的な投与量の第2の濃度の別の一或いは複数の化合物で前記ステントの第2の部分をコーティングするステップとを含むことを特徴とする実施態様(A)に記載の標的病変再狭窄の予防方法。
(7)前記別の一或いは複数の化合物が哺乳類ラパマイシン標的の高溶解性阻害薬を含むことを特徴とする実施態様(6)に記載の標的病変再狭窄の予防方法。
(8)更に、前記一或いは複数の化合物の組織内への透過性を高めるべく作用物質を添加することを含むことを特徴とする実施態様(A)に記載の標的病変再狭窄の予防方法。
(9)前記一或いは複数の化合物の腔内医療装置からのプロフィール放出が、前記治療的な投与量の第1の量の前記一或いは複数の化合物をポリマーと組み合わせてステントの第1の部分をコーティングするステップと、前記治療的な投与量の第2の量の前記一或いは複数の化合物をポリマーと組み合わせて前記ステントの第2の部分をコーティングするステップとを含み、前記第2の量が前記第1の量よりも多いことを特徴とする実施態様(A)に記載の標的病変再狭窄の予防方法。
(B)薬物送達装置であって、
腔内医療装置と、
標的病変再狭窄の治療のために前記腔内医療装置に所定のプロフィールで放出可能に設けられる治療的な投与量の一或いは複数の化合物とを含むことを特徴とする薬物送達装置。
(10)前記腔内医療装置がステントを含むことを特徴とする実施態様(B)に記載の薬物送達装置。
(12)前記一或いは複数の化合物が、高親和性の細胞質タンパク質であるFKBP12に結合する類似体、誘導体、および同族体を含み、ラパマイシンと同じ薬理学的特性を有することを特徴とする実施態様(B)に記載の薬物送達装置。
(13)前記腔内医療装置に所定のプロフィールで放出可能に設けられる治療的な投与量の前記一或いは複数の化合物が、前記腔内医療装置の第1の部分に設けられる第1の濃度の前記一或いは複数の化合物と、前記腔内医療装置の第2の部分に設けられる第2の濃度の前記一或いは複数の化合物とを含み、前記第2の濃度が前記第1の濃度よりも高いことを特徴とする実施態様(B)に記載の薬物送達装置。
(14)前記一或いは複数の化合物がラパマイシンを含むことを特徴とする実施態様(13)に記載の薬物送達装置。
(15)前記腔内医療装置に所定のプロフィールで放出可能に設けられる治療的な投与量の前記一或いは複数の化合物が、前記腔内医療装置の第1の部分に設けられる第1の濃度の前記一或いは複数の化合物と、前記腔内医療装置の第2の部分に設けられる第2の濃度の別の一或いは複数の化合物とを含むことを特徴とする実施態様(B)に記載の薬物送達装置。
(17)前記別の一或いは複数の化合物が哺乳類ラパマイシン標的の高溶解性阻害薬を含むことを特徴とする実施態様(15)に記載の薬物送達装置。
(18)更に、前記腔内医療装置に所定のプロフィールで放出可能に設けられる治療的な投与量の前記一或いは複数の化合物に含まれる前記一或いは複数の化合物の組織内への透過性を高めるための作用物質を含むことを特徴とする実施態様(B)に記載の薬物送達装置。
(19)前記腔内医療装置に所定のプロフィールで放出可能に設けられる治療的な投与量の前記一或いは複数の化合物が、前記腔内医療装置の第1の部分に設けられるポリマーと組み合わせた第1の量の前記一或いは複数の化合物と、前記腔内医療装置の第2の部分に設けられるポリマーと組み合わせた第2の量の前記一或いは複数の化合物とを含み、前記第2の量が前記第1の量よりも多いことを特徴とする実施態様(B)に記載の薬物送達装置。
102 帯域部分
104 連結部分
106 貯蔵領域
Claims (8)
- 薬物送達装置において、
第1の部分および第2の部分を含む腔内医療装置であって、前記第1の部分が該腔内医療装置の少なくとも1つの端部に近接している腔内医療装置と、
前記腔内医療装置に設けられたコーティングであって、標的病変再狭窄の治療のための治療的な投与量の1つ以上の化合物およびポリマーを含む、コーティングと、
を含み、
前記第1の部分に設けられた前記コーティングが、第1の量の前記1つ以上の化合物を含み、前記第2の部分に設けられた前記コーティングが、第2の量の前記1つ以上の化合物を含んでおり、前記第1の量が前記第2の量よりも多く、
前記ポリマーがトップコートを含み、前記第1の部分に設けられた前記トップコートが第1の厚さを有し、前記第2の部分に設けられた前記トップコートが第2の厚さを有し、前記第1の厚さが前記第2の厚さより小さい、薬物送達装置。 - 請求項1に記載の薬物送達装置であって、
前記第1の部分が、前記腔内医療装置の前記少なくとも1つの端部から2mm乃至3mmまでの領域である、薬物送達装置。 - 請求項1または2に記載の薬物送達装置であって、
前記第1の部分に設けられた前記コーティングの質量が、前記第2の部分に設けられた前記コーティングの質量よりも、10%乃至300%多い、薬物送達装置。 - 請求項1または2に記載の薬物送達装置であって、
前記第1の部分における前記1つ以上の化合物の濃度が、前記第2の部分における前記1つ以上の化合物の濃度よりも、33%乃至80%高い、薬物送達装置。 - 請求項1〜4のうちのいずれか1項に記載の薬物送達装置であって、
前記腔内医療装置が、ステントを含む、薬物送達装置。 - 請求項1〜4のうちのいずれか1項に記載の薬物送達装置であって、
前記1つ以上の化合物が、ラパマイシンを含む、薬物送達装置。 - 請求項1〜4のうちのいずれか1項に記載の薬物送達装置であって、
前記1つ以上の化合物が、高親和性細胞質タンパク質であるFKBP12に結合する類似体、誘導体、および、同族体を含み、ラパマイシンと同じ薬理学的特性を有する、薬物送達装置。 - 請求項1に記載の薬物送達装置であって、
前記ポリマーが、ポリフルオロコポリマーを含む、薬物送達装置。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US381986 | 1982-05-25 | ||
US431059 | 1989-11-03 | ||
US38198602P | 2002-05-20 | 2002-05-20 | |
US10/431,059 US7419678B2 (en) | 2000-05-12 | 2003-05-07 | Coated medical devices for the prevention and treatment of vascular disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004154541A JP2004154541A (ja) | 2004-06-03 |
JP4740525B2 true JP4740525B2 (ja) | 2011-08-03 |
Family
ID=29406971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003140878A Expired - Lifetime JP4740525B2 (ja) | 2002-05-20 | 2003-05-19 | 脈管疾患の予防および治療のためのコーティングされた医療装置 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7419678B2 (ja) |
EP (1) | EP1364628B1 (ja) |
JP (1) | JP4740525B2 (ja) |
AT (1) | ATE357194T1 (ja) |
AU (1) | AU2003204276B2 (ja) |
DE (1) | DE60312589T2 (ja) |
MX (1) | MXPA03004512A (ja) |
Families Citing this family (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8057816B2 (en) | 1997-09-26 | 2011-11-15 | Abbott Laboratories | Compositions and methods of administering paclitaxel with other drugs using medical devices |
US8257726B2 (en) * | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
US8394398B2 (en) * | 1997-09-26 | 2013-03-12 | Abbott Laboratories | Methods of administering rapamycin analogs with anti-inflammatories using medical devices |
US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
US7637948B2 (en) | 1997-10-10 | 2009-12-29 | Senorx, Inc. | Tissue marking implant |
US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US7179289B2 (en) | 1998-03-30 | 2007-02-20 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US20040254635A1 (en) * | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
US6862470B2 (en) | 1999-02-02 | 2005-03-01 | Senorx, Inc. | Cavity-filling biopsy site markers |
US7651505B2 (en) | 2002-06-17 | 2010-01-26 | Senorx, Inc. | Plugged tip delivery for marker placement |
US6725083B1 (en) | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
US20090030309A1 (en) | 2007-07-26 | 2009-01-29 | Senorx, Inc. | Deployment of polysaccharide markers |
US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US8498693B2 (en) | 1999-02-02 | 2013-07-30 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US6575991B1 (en) | 1999-06-17 | 2003-06-10 | Inrad, Inc. | Apparatus for the percutaneous marking of a lesion |
US7300662B2 (en) * | 2000-05-12 | 2007-11-27 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20040243097A1 (en) * | 2000-05-12 | 2004-12-02 | Robert Falotico | Antiproliferative drug and delivery device |
US20050002986A1 (en) * | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US7651696B2 (en) * | 2000-08-25 | 2010-01-26 | Nexeon Medical Systems, Inc. | Implantable device for treating disease states and methods of using same |
CA2424029C (en) | 2000-09-29 | 2008-01-29 | Cordis Corporation | Coated medical devices |
DE20122506U1 (de) * | 2000-10-16 | 2005-12-08 | Conor Medsystems, Inc., Menlo Park | Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens |
US6764507B2 (en) | 2000-10-16 | 2004-07-20 | Conor Medsystems, Inc. | Expandable medical device with improved spatial distribution |
US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
EP1919388B1 (en) | 2000-11-20 | 2012-12-26 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US20040220660A1 (en) * | 2001-02-05 | 2004-11-04 | Shanley John F. | Bioresorbable stent with beneficial agent reservoirs |
US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US7842083B2 (en) | 2001-08-20 | 2010-11-30 | Innovational Holdings, Llc. | Expandable medical device with improved spatial distribution |
US8460693B2 (en) | 2001-11-08 | 2013-06-11 | Atrium Medical Corporation | Intraluminal device with a coating containing synthetic fish oil and a therapeutic agent |
US7758636B2 (en) | 2002-09-20 | 2010-07-20 | Innovational Holdings Llc | Expandable medical device with openings for delivery of multiple beneficial agents |
CA2505576A1 (en) * | 2002-11-08 | 2004-05-27 | Conor Medsystems, Inc. | Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor |
US20060036158A1 (en) | 2003-11-17 | 2006-02-16 | Inrad, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US20040167572A1 (en) * | 2003-02-20 | 2004-08-26 | Roth Noah M. | Coated medical devices |
EP1610823B1 (en) | 2003-03-28 | 2011-09-28 | Innovational Holdings, LLC | Implantable medical device with continuous agent concentration gradient |
US7877133B2 (en) | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
US20050064011A1 (en) * | 2003-08-11 | 2005-03-24 | Young-Ho Song | Implantable or insertable medical devices containing phenolic compound for inhibition of restenosis |
US7785653B2 (en) * | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US20050273002A1 (en) | 2004-06-04 | 2005-12-08 | Goosen Ryan L | Multi-mode imaging marker |
US8652502B2 (en) * | 2003-12-19 | 2014-02-18 | Cordis Corporation | Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury |
US8747881B2 (en) | 2003-12-19 | 2014-06-10 | Cordis Corporation | Intraluminal medical devices in combination with therapeutic agents |
US20050249776A1 (en) * | 2003-12-19 | 2005-11-10 | Chen Chao C | Coated aneurysmal repair device |
WO2005068020A1 (en) * | 2004-01-02 | 2005-07-28 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
US7303758B2 (en) * | 2004-01-20 | 2007-12-04 | Cordis Corporation | Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury |
US7407684B2 (en) * | 2004-01-28 | 2008-08-05 | Boston Scientific Scimed, Inc. | Multi-step method of manufacturing a medical device |
US7806924B2 (en) * | 2004-02-18 | 2010-10-05 | Cordis Corporation | Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis |
US8431145B2 (en) | 2004-03-19 | 2013-04-30 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
US20070027523A1 (en) * | 2004-03-19 | 2007-02-01 | Toner John L | Method of treating vascular disease at a bifurcated vessel using coated balloon |
JP4949227B2 (ja) * | 2004-03-19 | 2012-06-06 | アボット・ラボラトリーズ | バルーンおよびプロテーゼからの多剤送達 |
US7875282B2 (en) * | 2004-03-22 | 2011-01-25 | Cordis Corporation | Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury |
US8007737B2 (en) | 2004-04-14 | 2011-08-30 | Wyeth | Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices |
US20060240065A1 (en) * | 2005-04-26 | 2006-10-26 | Yung-Ming Chen | Compositions for medical devices containing agent combinations in controlled volumes |
US8709469B2 (en) | 2004-06-30 | 2014-04-29 | Abbott Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
EP1791496B1 (en) | 2004-08-31 | 2019-07-31 | C.R. Bard, Inc. | Self-sealing ptfe graft with kink resistance |
US8124127B2 (en) | 2005-10-15 | 2012-02-28 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US20060067976A1 (en) | 2004-09-28 | 2006-03-30 | Atrium Medical Corporation | Formation of barrier layer |
US8263102B2 (en) | 2004-09-28 | 2012-09-11 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US7976517B2 (en) * | 2004-09-30 | 2011-07-12 | Codman & Shurtleff, Inc. | Fluid management flow implants of improved occlusion resistance |
US8419656B2 (en) | 2004-11-22 | 2013-04-16 | Bard Peripheral Vascular, Inc. | Post decompression marker introducer system |
US10357328B2 (en) | 2005-04-20 | 2019-07-23 | Bard Peripheral Vascular, Inc. and Bard Shannon Limited | Marking device with retractable cannula |
WO2006133373A2 (en) * | 2005-06-08 | 2006-12-14 | C.R. Bard Inc. | Grafts and stents having inorganic bio-compatible calcium salt |
JP2009501027A (ja) | 2005-06-17 | 2009-01-15 | シー・アール・バード・インコーポレイテツド | 締付後のよじれ耐性を有する血管移植片 |
ES2574780T3 (es) * | 2005-09-06 | 2016-06-22 | C.R. Bard, Inc. | Injerto de liberación de fármacos |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
CA2562580C (en) | 2005-10-07 | 2014-04-29 | Inrad, Inc. | Drug-eluting tissue marker |
US8636794B2 (en) | 2005-11-09 | 2014-01-28 | C. R. Bard, Inc. | Grafts and stent grafts having a radiopaque marker |
US20070116736A1 (en) * | 2005-11-23 | 2007-05-24 | Argentieri Dennis C | Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury |
US7976891B1 (en) | 2005-12-16 | 2011-07-12 | Advanced Cardiovascular Systems, Inc. | Abluminal stent coating apparatus and method of using focused acoustic energy |
WO2007098270A2 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same |
US20070224237A1 (en) * | 2006-03-24 | 2007-09-27 | Julia Hwang | Barbed sutures having a therapeutic agent thereon |
US7775178B2 (en) | 2006-05-26 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Stent coating apparatus and method |
JP5541593B2 (ja) * | 2006-08-15 | 2014-07-09 | アボット ラボラトリーズ | ラパマイシン類似体及びパクリタキセルを含む組成物及び薬物送達システム |
US9198749B2 (en) | 2006-10-12 | 2015-12-01 | C. R. Bard, Inc. | Vascular grafts with multiple channels and methods for making |
US8064987B2 (en) | 2006-10-23 | 2011-11-22 | C. R. Bard, Inc. | Breast marker |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
EP2083875B1 (en) | 2006-11-06 | 2013-03-27 | Atrium Medical Corporation | Coated surgical mesh |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9579077B2 (en) | 2006-12-12 | 2017-02-28 | C.R. Bard, Inc. | Multiple imaging mode tissue marker |
ES2432572T3 (es) | 2006-12-18 | 2013-12-04 | C.R. Bard, Inc. | Marcador de biopsia con propiedades de obtención de imágenes generadas in situ |
EP2125058B1 (en) | 2007-02-07 | 2014-12-03 | Cook Medical Technologies LLC | Medical device coatings for releasing a therapeutic agent at multiple rates |
PT2114924E (pt) | 2007-02-27 | 2012-04-03 | Vertex Pharma | Co-cristais e composições farmacêuticas que compreendem os mesmos |
MX2010002407A (es) | 2007-08-30 | 2010-03-26 | Vertex Pharma | Cocristales y composiciones farmaceuticas que los comprenden. |
JP2011506341A (ja) | 2007-12-07 | 2011-03-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 固形型の1−エチル−3−(5−(5−フルオロピリジン−3−イル)−7−(ピリミジン−2−イル)−1H−ベンゾ[d]イミダゾール−2−イル)ウレア |
WO2009099767A2 (en) | 2008-01-31 | 2009-08-13 | C.R. Bard, Inc. | Biopsy tissue marker |
US20110129526A1 (en) | 2008-02-20 | 2011-06-02 | The General Hospital Corporation | Compositions and methods for treating vascular disease |
WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US9327061B2 (en) | 2008-09-23 | 2016-05-03 | Senorx, Inc. | Porous bioabsorbable implant |
WO2010077244A1 (en) | 2008-12-30 | 2010-07-08 | C.R. Bard Inc. | Marker delivery device for tissue marker placement |
WO2010093889A2 (en) | 2009-02-13 | 2010-08-19 | Vertex Pharmaceuticals Incorporated | Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US8951595B2 (en) | 2009-12-11 | 2015-02-10 | Abbott Cardiovascular Systems Inc. | Coatings with tunable molecular architecture for drug-coated balloon |
US8480620B2 (en) | 2009-12-11 | 2013-07-09 | Abbott Cardiovascular Systems Inc. | Coatings with tunable solubility profile for drug-coated balloon |
WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
AU2012205415B2 (en) | 2011-01-14 | 2017-02-02 | Spero Therapeutics, Inc. | Pyrimidine gyrase and topoisomerase IV inhibitors |
US10166128B2 (en) | 2011-01-14 | 2019-01-01 | W. L. Gore & Associates. Inc. | Lattice |
US9839540B2 (en) | 2011-01-14 | 2017-12-12 | W. L. Gore & Associates, Inc. | Stent |
AU2012205419B2 (en) | 2011-01-14 | 2016-12-15 | Spero Therapeutics, Inc. | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea |
US9187953B2 (en) | 2011-03-23 | 2015-11-17 | Rytec Corporation | Side column configuration for overhead roll-up door assemblies |
US9744033B2 (en) | 2011-04-01 | 2017-08-29 | W.L. Gore & Associates, Inc. | Elastomeric leaflet for prosthetic heart valves |
CN103702994B (zh) | 2011-06-20 | 2016-03-23 | 沃泰克斯药物股份有限公司 | 旋转酶和拓扑异构酶抑制剂的磷酸酯 |
US9554806B2 (en) | 2011-09-16 | 2017-01-31 | W. L. Gore & Associates, Inc. | Occlusive devices |
US9510935B2 (en) | 2012-01-16 | 2016-12-06 | W. L. Gore & Associates, Inc. | Articles including expanded polytetrafluoroethylene membranes with serpentine fibrils and having a discontinuous fluoropolymer layer thereon |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
WO2014015105A1 (en) | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
US9283072B2 (en) | 2012-07-25 | 2016-03-15 | W. L. Gore & Associates, Inc. | Everting transcatheter valve and methods |
US9931193B2 (en) | 2012-11-13 | 2018-04-03 | W. L. Gore & Associates, Inc. | Elastic stent graft |
US9968443B2 (en) | 2012-12-19 | 2018-05-15 | W. L. Gore & Associates, Inc. | Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet |
US9144492B2 (en) | 2012-12-19 | 2015-09-29 | W. L. Gore & Associates, Inc. | Truncated leaflet for prosthetic heart valves, preformed valve |
US9101469B2 (en) | 2012-12-19 | 2015-08-11 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with leaflet shelving |
US10279084B2 (en) | 2012-12-19 | 2019-05-07 | W. L. Gore & Associates, Inc. | Medical balloon devices and methods |
WO2014171184A1 (ja) | 2013-04-16 | 2014-10-23 | 株式会社カネカ | 医療用管状体 |
US11911258B2 (en) | 2013-06-26 | 2024-02-27 | W. L. Gore & Associates, Inc. | Space filling devices |
USD716450S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716451S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715442S1 (en) | 2013-09-24 | 2014-10-14 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715942S1 (en) | 2013-09-24 | 2014-10-21 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
SG11201602962PA (en) | 2013-10-17 | 2016-05-30 | Vertex Pharma | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
US10842918B2 (en) | 2013-12-05 | 2020-11-24 | W.L. Gore & Associates, Inc. | Length extensible implantable device and methods for making such devices |
US9827094B2 (en) | 2014-09-15 | 2017-11-28 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with retention elements |
US10286116B2 (en) | 2015-04-15 | 2019-05-14 | Mayo Foundation For Medical Education And Research | Methods and materials for reducing venous neointimal hyperplasia of an arteriovenous fistula or graft |
ES2908460T3 (es) | 2015-05-14 | 2022-04-29 | Gore & Ass | Dispositivos para la oclusión de un apéndice auricular |
ES2956016T3 (es) | 2016-04-21 | 2023-12-11 | Gore & Ass | Endoprótesis ajustables diametralmente |
AU2018342222B2 (en) | 2017-09-27 | 2021-05-20 | Edwards Lifesciences Corporation | Prosthetic valve with expandable frame and associated systems and methods |
US11173023B2 (en) | 2017-10-16 | 2021-11-16 | W. L. Gore & Associates, Inc. | Medical devices and anchors therefor |
US11439502B2 (en) | 2017-10-31 | 2022-09-13 | W. L. Gore & Associates, Inc. | Medical valve and leaflet promoting tissue ingrowth |
US11497601B2 (en) | 2019-03-01 | 2022-11-15 | W. L. Gore & Associates, Inc. | Telescoping prosthetic valve with retention element |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US5500013A (en) * | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
DE4222380A1 (de) * | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | In den Körper eines Patienten perkutan implantierbare Endoprothese |
ZA9710342B (en) * | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
PT981381E (pt) * | 1997-05-12 | 2007-04-30 | Metabolix Inc | Poli-hidroxialcanoatos para aplicações in vivo |
US20060198867A1 (en) * | 1997-09-25 | 2006-09-07 | Abbott Laboratories, Inc. | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
US20010029351A1 (en) * | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
WO1999056663A2 (en) * | 1998-05-05 | 1999-11-11 | Scimed Life Systems, Inc. | Stent with smooth ends |
US6153252A (en) * | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US6335029B1 (en) * | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US6790228B2 (en) * | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6759054B2 (en) * | 1999-09-03 | 2004-07-06 | Advanced Cardiovascular Systems, Inc. | Ethylene vinyl alcohol composition and coating |
AU2623201A (en) * | 1999-12-30 | 2001-07-16 | Kam W Leong | Controlled delivery of therapeutic agents by insertable medical devices |
US6818247B1 (en) * | 2000-03-31 | 2004-11-16 | Advanced Cardiovascular Systems, Inc. | Ethylene vinyl alcohol-dimethyl acetamide composition and a method of coating a stent |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
ATE307625T1 (de) | 2000-05-12 | 2005-11-15 | Cordis Corp | Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen |
CA2424029C (en) | 2000-09-29 | 2008-01-29 | Cordis Corporation | Coated medical devices |
ATE302029T1 (de) | 2000-09-29 | 2005-09-15 | Cordis Corp | Beschichtete medizinische geräte und verfahren zur sterilisation |
US7261735B2 (en) * | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US6752829B2 (en) * | 2001-01-30 | 2004-06-22 | Scimed Life Systems, Inc. | Stent with channel(s) for containing and delivering a biologically active material and method for manufacturing the same |
WO2002069848A2 (en) * | 2001-03-06 | 2002-09-12 | Board Of Regents, The University Of Texas System | Apparatus for stent deployment with delivery of bioactive agents |
US7056338B2 (en) * | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US6743463B2 (en) * | 2002-03-28 | 2004-06-01 | Scimed Life Systems, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US7169178B1 (en) * | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
US8652502B2 (en) * | 2003-12-19 | 2014-02-18 | Cordis Corporation | Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury |
US7303758B2 (en) * | 2004-01-20 | 2007-12-04 | Cordis Corporation | Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury |
US8828416B2 (en) * | 2004-03-09 | 2014-09-09 | Cordis Corporation | Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury |
US7695731B2 (en) * | 2004-03-22 | 2010-04-13 | Cordis Corporation | Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury |
US7875282B2 (en) * | 2004-03-22 | 2011-01-25 | Cordis Corporation | Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury |
-
2003
- 2003-05-07 US US10/431,059 patent/US7419678B2/en not_active Expired - Lifetime
- 2003-05-19 JP JP2003140878A patent/JP4740525B2/ja not_active Expired - Lifetime
- 2003-05-19 AT AT03253128T patent/ATE357194T1/de not_active IP Right Cessation
- 2003-05-19 DE DE60312589T patent/DE60312589T2/de not_active Expired - Lifetime
- 2003-05-19 EP EP03253128A patent/EP1364628B1/en not_active Expired - Lifetime
- 2003-05-20 AU AU2003204276A patent/AU2003204276B2/en not_active Expired
- 2003-05-20 MX MXPA03004512A patent/MXPA03004512A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2003204276B2 (en) | 2007-09-20 |
EP1364628B1 (en) | 2007-03-21 |
ATE357194T1 (de) | 2007-04-15 |
US20030216699A1 (en) | 2003-11-20 |
DE60312589T2 (de) | 2007-12-06 |
AU2003204276A1 (en) | 2003-12-11 |
US7419678B2 (en) | 2008-09-02 |
DE60312589D1 (de) | 2007-05-03 |
MXPA03004512A (es) | 2004-09-06 |
EP1364628A1 (en) | 2003-11-26 |
JP2004154541A (ja) | 2004-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4740525B2 (ja) | 脈管疾患の予防および治療のためのコーティングされた医療装置 | |
JP5579353B2 (ja) | 抗炎症剤および薬物配給装置 | |
EP1609494B1 (en) | Heparin barrier coating for controlled drug release | |
JP6081047B2 (ja) | 薬物溶出リザーバを備えるベアメタルステント | |
EP1891991B1 (en) | Therapeutic agent elution control process | |
JP2005305167A (ja) | 脈管の病気の予防および治療のための薬物/薬物配給システム | |
US20020005206A1 (en) | Antiproliferative drug and delivery device | |
US20020007213A1 (en) | Drug/drug delivery systems for the prevention and treatment of vascular disease | |
US20020007214A1 (en) | Drug/drug delivery systems for the prevention and treatment of vascular disease | |
JP2005334646A (ja) | 抗増殖薬および配給装置 | |
KR20110005222A (ko) | 라파마이신 저장기 용출 스텐트 | |
JP2005305168A (ja) | 脈管の病気の予防および治療のための薬物/薬物配給システム | |
AU2001259774A1 (en) | Delivery devices for treatment of vascular disease | |
AU2001261579A1 (en) | Delivery systems for treatment of vascular disease | |
AU2001263113A1 (en) | Drug/drug delivery systems for the prevention and treatment of vascular disease | |
AU2001263112A1 (en) | Delivery systems for the prevention and treatment of vascular disease | |
JP4994558B2 (ja) | 脈管の病気の治療のための配給装置 | |
JP2005312967A (ja) | 脈管の病気の予防および治療のための薬物/薬物配給システム | |
JP2010259793A (ja) | 二薬ステント | |
CA2429059C (en) | Coated medical devices for the prevention and treatment of vascular disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060426 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090626 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101125 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110412 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110502 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4740525 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140513 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |